Short answer
Tango Therapeutics, Inc. (TNGX) filed an 8-K current report with the SEC on May 8, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). CFO Daniella Beckman departed effective April 15, 2026; last employment day May 1, 2026.
Tango Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CFO Daniella Beckman departed effective April 15, 2026; last employment day May 1, 2026
- Separation package includes 12 months’ base-salary severance and COBRA reimbursement for up to 12 months
- Equity acceleration covers awards that would have vested during an additional 24 months after May 1, 2026
- Vested option exercise period extended through August 31, 2026
- Benefits conditioned on Beckman’s general release of the Company
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tango Therapeutics, Inc. 8-K filings
Get the next TNGX 8-K as it lands
Follow TNGX for push alerts, or ask the research agent what this filing means.